TY - JOUR
T1 - Risk factors for portopulmonary hypertension in patients with cirrhosis
T2 - a prospective, multicenter study
AU - Atsukawa, Masanori
AU - Tsubota, Akihito
AU - Kondo, Chisa
AU - Koyano, Kaori Shioda
AU - Ishikawa, Toru
AU - Toyoda, Hidenori
AU - Takaguchi, Koichi
AU - Watanabe, Tsunamasa
AU - Matsuura, Kentaro
AU - Ogawa, Chikara
AU - Hiraoka, Atsushi
AU - Okubo, Hironao
AU - Tateyama, Masakuni
AU - Uojima, Haruki
AU - Nozaki, Akito
AU - Chuma, Makoto
AU - Kato, Keizo
AU - Mikami, Shigeru
AU - Tani, Joji
AU - Morishita, Asahiro
AU - Kawata, Kazuhito
AU - Tada, Toshifumi
AU - Furuichi, Yoshihiro
AU - Okubo, Tomomi
AU - Kawano, Tadamichi
AU - Arai, Taeang
AU - Kawabe, Naoto
AU - Kawamura, Naohiro
AU - Ikegami, Tadashi
AU - Nakamuta, Makoto
AU - Shigefuku, Ryuta
AU - Iwasa, Motoh
AU - Tanaka, Yasuhito
AU - Hatano, Masaru
AU - Iwakiri, Katsuhiko
N1 - Publisher Copyright:
© 2022, Asian Pacific Association for the Study of the Liver.
PY - 2023/2
Y1 - 2023/2
N2 - Background: Tricuspid regurgitation pressure gradient (TRPG) measurement by echocardiography is recommended as the most objective examination to detect portopulmonary hypertension (PoPH). This study aimed to identify factors associated with a high TRPG in patients with cirrhosis and develop a scoring model for identifying patients who are most likely to benefit from echocardiography investigations. Results: A total of 486 patients who underwent echocardiography were randomly allocated to the derivation and validation sets at a ratio of 2:1. Of the patients, 51 (10.5%) had TRPG ≥ 35 mmHg. The median brain natriuretic peptide (BNP) was 39.5 pg/mL. Shortness of breath (SOB) was reported by 91 (18.7%) patients. In the derivation set, multivariate analysis identified female gender, shortness of breath, and BNP ≥ 48.9 pg/mL as independent factors for TRPG ≥ 35 mmHg. The risk score for predicting TRPG ≥ 35 mmHg was calculated as follows: − 3.596 + 1.250 × gender (female: 1, male: 0) + 1.093 × SOB (presence: 1, absence: 0) + 0.953 × BNP (≥ 48.9 pg/mL: 1, < 48.9 pg/mL: 0). The risk score yielded sensitivity of 66.7%, specificity of 75.3%, positive predictive value of 25.5%, negative predict value of 94.3%, and predictive accuracy of 74.4% for predicting TRPG ≥ 35 mmHg. These results were almost similar in the validation set, indicating the reproducibility and validity of the risk score. Conclusions: This study clarified the characteristics of patients with suspected PoPH and developed a scoring model for identifying patients at high risk of PoPH, which may be used in selecting patients that may benefit from echocardiography.
AB - Background: Tricuspid regurgitation pressure gradient (TRPG) measurement by echocardiography is recommended as the most objective examination to detect portopulmonary hypertension (PoPH). This study aimed to identify factors associated with a high TRPG in patients with cirrhosis and develop a scoring model for identifying patients who are most likely to benefit from echocardiography investigations. Results: A total of 486 patients who underwent echocardiography were randomly allocated to the derivation and validation sets at a ratio of 2:1. Of the patients, 51 (10.5%) had TRPG ≥ 35 mmHg. The median brain natriuretic peptide (BNP) was 39.5 pg/mL. Shortness of breath (SOB) was reported by 91 (18.7%) patients. In the derivation set, multivariate analysis identified female gender, shortness of breath, and BNP ≥ 48.9 pg/mL as independent factors for TRPG ≥ 35 mmHg. The risk score for predicting TRPG ≥ 35 mmHg was calculated as follows: − 3.596 + 1.250 × gender (female: 1, male: 0) + 1.093 × SOB (presence: 1, absence: 0) + 0.953 × BNP (≥ 48.9 pg/mL: 1, < 48.9 pg/mL: 0). The risk score yielded sensitivity of 66.7%, specificity of 75.3%, positive predictive value of 25.5%, negative predict value of 94.3%, and predictive accuracy of 74.4% for predicting TRPG ≥ 35 mmHg. These results were almost similar in the validation set, indicating the reproducibility and validity of the risk score. Conclusions: This study clarified the characteristics of patients with suspected PoPH and developed a scoring model for identifying patients at high risk of PoPH, which may be used in selecting patients that may benefit from echocardiography.
UR - http://www.scopus.com/inward/record.url?scp=85143381598&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143381598&partnerID=8YFLogxK
U2 - 10.1007/s12072-022-10456-y
DO - 10.1007/s12072-022-10456-y
M3 - Article
C2 - 36477691
AN - SCOPUS:85143381598
SN - 1936-0533
VL - 17
SP - 139
EP - 149
JO - Hepatology International
JF - Hepatology International
IS - 1
ER -